Long-Term Thrombosis Rates Similar for Drug-Eluting Stents

Similar rates of stent thrombosis seen at three years for zotarolimus- and sirolimus-eluting stents

WEDNESDAY, Aug. 29 (HealthDay News) -- Two types of drug-eluting stents with distinct antiproliferative properties have similar long-term rates of stent thrombosis and outcomes, including death and heart attack, according to a study published online Aug. 27 in The Lancet to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

Edoardo Camenzind, M.D., from the University of Geneva, and colleagues randomly assigned 8,709 patients undergoing coronary artery procedures to receive the Endeavor zotarolimus-eluting stent (E-ZES; 4,357 patients) or the Cypher sirolimus-eluting stent (C-SES; 4,352 patients).

The researchers found that, after three years, the rates of definite or probable stent thrombosis were similar for the E-ZES (1.4 percent; predicted, 1.5 percent) and C-SES (1.8 percent; predicted, 2.5 percent) groups (hazard ratio, 0.81; P = 0.22). The two groups also had similar rates of outcomes, including death, myocardial infarction, stroke, and major bleeding. Dual antiplatelet treatment use was similar in both groups and was used by 96 percent of patients at discharge, 88 percent at one year, 37 percent at two years, and 30 percent at three years.

"No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at three years," Camenzind and colleagues conclude. "Time analysis suggests a difference in definite or probable stent thrombosis between groups is emerging over time, and a longer follow-up is therefore needed given the clinical relevance of stent thrombosis."

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Medtronic, which funded the study and manufactures E-ZES, and Cordis, which manufactures C-SES.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Abdominal Pain: An Approach to a Challenging Diagnosis
AACN Advanced Critical Care, July/September 2014
Free access will expire on October 13, 2014.


HIPAA Compliance Practice Tips
Professional Case Management, July/August 2014
Free access will expire on September 29, 2014.


Follow the leader: How does “followership” influence nurse burnout?
Nursing Management, August 2014
Free access will expire on September 29, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events